PL3082858T3 - Środek wiążący adrenomedulinę do zastosowania w terapii nowotworu - Google Patents
Środek wiążący adrenomedulinę do zastosowania w terapii nowotworuInfo
- Publication number
- PL3082858T3 PL3082858T3 PL14830958T PL14830958T PL3082858T3 PL 3082858 T3 PL3082858 T3 PL 3082858T3 PL 14830958 T PL14830958 T PL 14830958T PL 14830958 T PL14830958 T PL 14830958T PL 3082858 T3 PL3082858 T3 PL 3082858T3
- Authority
- PL
- Poland
- Prior art keywords
- adrenomedullin
- cancer
- therapy
- binder
- adrenomedullin binder
- Prior art date
Links
- 102000004379 Adrenomedullin Human genes 0.000 title 1
- 101800004616 Adrenomedullin Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 title 1
- 239000011230 binding agent Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13199000 | 2013-12-20 | ||
| PCT/EP2014/078870 WO2015092021A1 (en) | 2013-12-20 | 2014-12-19 | Adrenomedullin binder for use in therapy of cancer |
| EP14830958.6A EP3082858B1 (en) | 2013-12-20 | 2014-12-19 | Adrenomedullin binder for use in therapy of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3082858T3 true PL3082858T3 (pl) | 2021-09-27 |
Family
ID=49876456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14830958T PL3082858T3 (pl) | 2013-12-20 | 2014-12-19 | Środek wiążący adrenomedulinę do zastosowania w terapii nowotworu |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10793626B2 (pl) |
| EP (1) | EP3082858B1 (pl) |
| JP (1) | JP6673847B2 (pl) |
| ES (1) | ES2865303T3 (pl) |
| PL (1) | PL3082858T3 (pl) |
| WO (1) | WO2015092021A1 (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4061944A1 (en) * | 2019-11-22 | 2022-09-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Inhibitors of adrenomedullin for the treatment of acute myeloid leukemia by eradicating leukemic stem cells |
| BR112022017890A2 (pt) * | 2020-03-16 | 2022-11-01 | Sphingotec Gmbh | Proadrenomedulina ou fragmento da mesma em pacientes infectados com coronavírus e tratamentos com ligante contra adrenomedulina |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69602756T2 (de) * | 1995-08-18 | 2000-02-10 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville | Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie |
| US20050175619A1 (en) * | 2004-02-05 | 2005-08-11 | Robert Duffy | Methods of producing antibody conjugates |
| WO2007136893A2 (en) * | 2006-02-10 | 2007-11-29 | Genentech, Inc. | Anti-fgf19 antibodies and methods using same |
| FI3553084T3 (fi) * | 2011-11-16 | 2023-03-03 | Adrenomed Ag | Anti-adrenomedulliinivasta-aine (ADM) tai anti-ADM-vasta-ainefragmentti tai anti-ADM-non-Ig-skaffoldi elimen toimintahäiriön tai elimen vajaatoiminnan ehkäisemiseksi tai pienentämiseksi kroonisen tai akuutin taudin tai akuutin tilan omaavassa potilaassa |
| JP6224608B2 (ja) * | 2011-11-16 | 2017-11-01 | アドレノメト アクチェンゲゼルシャフト | 血液循環を安定化させるための、患者の急性疾患又は急性病態の治療法における使用に向けた、抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 |
-
2014
- 2014-12-19 WO PCT/EP2014/078870 patent/WO2015092021A1/en not_active Ceased
- 2014-12-19 EP EP14830958.6A patent/EP3082858B1/en not_active Revoked
- 2014-12-19 US US15/105,712 patent/US10793626B2/en active Active
- 2014-12-19 PL PL14830958T patent/PL3082858T3/pl unknown
- 2014-12-19 ES ES14830958T patent/ES2865303T3/es active Active
- 2014-12-19 JP JP2016560037A patent/JP6673847B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3082858B1 (en) | 2021-01-27 |
| US20160319007A1 (en) | 2016-11-03 |
| EP3082858A1 (en) | 2016-10-26 |
| JP2017508781A (ja) | 2017-03-30 |
| US10793626B2 (en) | 2020-10-06 |
| WO2015092021A1 (en) | 2015-06-25 |
| ES2865303T3 (es) | 2021-10-15 |
| JP6673847B2 (ja) | 2020-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274318A (en) | Cancer treatment with rapamycin target site kinase inhibitors | |
| IL245731A0 (en) | Combined treatment for cancer | |
| GB201322725D0 (en) | Cancer therapy | |
| SG10201801433XA (en) | Composition and vaccine for treating prostate cancer | |
| GB2516814B (en) | Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer | |
| IL245281A0 (en) | Methods and preparations for the treatment of cancer | |
| DK3010519T3 (en) | Oncolytic adenovirus for use in a treatment of brain cancer | |
| IL234639B (en) | Cancer treatment with rapamycin target site kinase inhibitors | |
| ZA201406706B (en) | Treatment of cancer with tor kinase inhibitors | |
| IL234641A0 (en) | Cancer treatment with rapamycin target site kinase inhibitors | |
| SG11201509707QA (en) | Cancer therapy | |
| IL244353A0 (en) | Compounds and use for cancer treatment | |
| SG11201507847UA (en) | Cancer therapy | |
| ZA201507755B (en) | Tumor-selective combination therapy | |
| IL238453A0 (en) | Trans-clomiphene for use in cancer treatment | |
| PL3071192T3 (pl) | Związek kurkufenol do zastosowania w leczeniu nowotworu | |
| EP2961412A4 (en) | CANCER THERAPY | |
| SI2872176T1 (sl) | Karboranilporfirin za uporabo pri zdravljenju raka | |
| PL3082858T3 (pl) | Środek wiążący adrenomedulinę do zastosowania w terapii nowotworu | |
| GB201518731D0 (en) | Tumour Therapy | |
| GB201317213D0 (en) | Cancer Therapy | |
| GB201322958D0 (en) | Uses of oligouronates in cancer treatment | |
| PL3010513T3 (pl) | Skojarzenie RO5503781 i kapecytabiny do leczenia raka | |
| GB201308365D0 (en) | Tumour therapy | |
| ZA201502294B (en) | Treatment of cancer with tor kinase inhibitors |